History and practice: Antibodies in infectious diseases

Microbiology Spectrum

Volumn 3, Issue 2, 2015, Pages

  Hey, Adam ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ANIMAL; COMMUNICABLE DISEASES; HISTORY; HUMAN; PASSIVE IMMUNIZATION; PROCEDURES;

ANIMALS; ANTIBODIES; COMMUNICABLE DISEASES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION, PASSIVE;

EID: 84959055157     PISSN: None     EISSN: 21650497     Source Type: Journal    
DOI: 10.1128/microbiolspec.AID-0026-2014     Document Type: Article

References (41)

1. Casadevall A, SharffMD. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 38:1695-1702.
2. Casadevall A. 1996. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 2:200-208.
3. Behring EA, Kitasato S. 1890. Ueber das zustandekommen der diptherie-immunität und der tetanus-immunität bei thieren. Deutch Med Woch 49:1113-1114.
4. Klemperer G, Klemperer F. 1891. Versuche uber immunisirung und heilung bei der pneumokokkeninfection. Berlin Klin Wochenschr 28: 833-835.
5. Flexner S, Jobling JW. 1908. Serum treatment of epidemic cerebrospinal meningitis. J Exp Med 10:141-195.
6. Rosington B. 2013. The drugs won't work: top doctor warns of "apocalypse" in 20 years as bugs become resistant to antibiotics. Daily Mirror, January 24.
7. WHO. 2014. Ebola response roadmap update report. http://www.who.int/csr/resources/publications/ebola/response-roadmap/en/.
8. Chan CEZ, Chan AHY, Hanson BJ, Ooi EE. 2009. The use of antibodies in the treatment of infectious diseases. Singapore Med J 50:663-672.
9. Berry JD, Gaudet RG. 2011. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. New Biotechnol 28:489-501.
10. Cauza K, Hinterhuber G, Dingelmaier-Hovorka R, Brugger K, Klosner G, Horvat R, WolffK, Foedinger D. 2005. Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes. J Invest Dermatol 124:132-139.
11. Marasco WA, Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25:1421-1434.
12. Wrammert J, Koutsonanos D, Li G-M, Edupganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Metha A, Razave B, DelRio C, Zheng N-Y, Lee J-H, Huang M, All Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnel CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan M, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
13. Köhler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
14. Casadevall A, Dadachova E, Pirofski LA. 2004. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695-703.
15. Triggle N. Antibiotic treatments from GPs "fail 15% of the time". BBC News, Health, September 25.
16. Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum J. 2006. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr Pharm Des 12:2007-2015.
17. Flego M, Ascione A, Cianfriglia M, Vella S. 2013. Clinical development of monoclonal antibody-based therapy drugs in HIV and HCV diseases. BMC Med 11:1-17.
18. de Kruif J, Bakker ABH, Marissen WE, Arjen Kramer R, Throsby M, Rupprecht CE, Goudsmit J. 2007. A human monoclonal antibody cocktail as a novel component of rabies post-exposure prophylaxis. Annu Rev Med 50:359-368.
19. Lazar GA, Dang W, Karki S, Vafa, O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC. 2006. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010.
20. Shields RL, Namenuk AK, Hong K, Meng YG, Rae, J, Briggs J, Xie D, Lai J, Stadlen A, Li B. 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 276:6591-6604.
21. Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM, Webster C, Jermutus L, Lund J. 2011. A variant human IgG1-Fc mediates improved ADCC. Protein Eng Des Sel 24:671-678.
22. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K. 2004. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of Fc-q gammaRIIIa functional polymorphism. Clin Cancer Res 10: 6248-6255.
23. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JGJ, Parren PWHI. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 75:12161-12168.
24. Hessell AJ, Hangartner L, Hunter M, Havenith CD, Beursken FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-104
25. Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 281:23514-23524.
26. Saylor C, Dadachova E, Casadevall A. 2009. Monoclonal antibodybased therapies for microbial diseases. Vaccine 275:G38-G46.
27. Hall AE, Domanski PJ, Vernachio JH, Syrbeys PJ, Gorovits EL, Johnson MA, Ross JM, Patti JM. 2003. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71:6864-6870.
28. Bebbington C, Yarranton G. 2008. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 19:613-619.
29. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS, Palmer KG, Trautman MS, Escobedo M, Meissner HC, Sasidharan P, Fretz J, Kokai-Kun JF, Mond JJ. 2011. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128:271-279.
30. Weintraub JA, Hilton JF, White JM, Hoover CI, WycoffKL, Yu L, Larrick JW, Featherstone JD. 2005. Clinical trial of a plant-derived antibody on recolonization of mutans streptococci. Caries Res 19:241-250.
31. Baer M, Sawa T, Flynn P. 2009. An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent anti-bacterial activity. Infect Immun 77:1083-1090.
32. Secher T, Fauconnier L, Szade A. 2011. Anti-pseudomonas aeruginosa serotype 011 LPS immunoglobulinMmonoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. J Antimicrob Chemother 66:1100-1109.
33. Migone T, Subramanian GM, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135-144.
34. Lowy I, Molrine DC, Leav BA. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197-205.
35. Ter Meulen J. 2011. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin N Am 25:798-802.
36. Broering TJ, Garrity KA, Boatright NK. 2009. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83:12473-12482.
37. Soares MM, King SW, Thorpe PE. 2008. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14:1357-1362.
38. Bruno BJ, Jacobson JM. 2010. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother 65:1839-1841.
39. Li L, Sun T, Yang K. 2010. Monoclonal CCR5 antibody for treatment of people with HIV infection (review). Cochrane Database Syst Rev 8: CD008439.
40. Quiambao B, Bakker A, Bermal NN. 2009. Evaluation of the safety and neutralizing activity of CL184, a monoclonal antibody cocktail against rabies, in a phase II study in healthy adolescents and children. Quebec, Canada: Presentation at RITA XX, Rabies in the Americas.
41. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA. 2005. Phase I evaluation of the safety and pharmacokinetics of murinederived anticryptococcal antibody 18b7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49:952-958.